Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data

He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in atopic dermatitis patients by the end of the year. Plus, discussing a new target Kymera recently announced for other immuno-inflammatory diseases, IRF5.